Currently, management of type 1 diabetes involves a lifetime of monitoring insulin levels and administering insulin with an injection or pump, an inexact and troublesome process for diabetics and their carers.
The safety and ease of care may soon be significantly improved given the results of a recently completed trial of a new type of artificial pancreas, the Control-IQ system. The system monitors a patient’s blood glucose levels and automatically administers an adjusted dose of insulin as needed.
Over the course of the six-month trial, patients using the system were in the target blood glucose range of 70 to 180 milligrams per deciliter (mg/dl) for an average of 2.6 hours longer per day than previously.
The system also improved participants’ control overnight, a time when many people’s levels drop.
One of the 100 participants using the new system developed diabetic ketoacidosis due to an equipment issue, but despite this, the trial results indicate the device could soon be available for use in the US.
>> Read the original article here
Source: Medical News Today